Form 4: In8bio Director and 10% Owner Bios Funds Report Changes in Beneficial Ownership

Aaron G.L. Fletcher, along with related Bios Funds, reported transactions involving In8bio, Inc. securities, including the purchase of units consisting of pre-funded warrants and Series C warrants, as well as amendments to existing Series A warrants.

Summary

• On October 11, 2024, Aaron G.L. Fletcher, a director and 10% owner of In8bio, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report also covers transactions by various Bios Funds, including Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus Co-Invest I, Bios Clinical Opportunity Fund, Bios Equity COF, Bios Capital Management, and Bios Advisors GP, LLC.
• On October 4, 2024, Bios Clinical Opportunity Fund purchased 709,040 units from In8bio at $0.3949 per unit in a private placement.
• Each unit consisted of one pre-funded warrant to purchase one share of common stock and one Series C warrant to purchase one share of common stock.
• The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately until fully exercised.
• Existing Series A warrants issued to Bios COF on December 13, 2023, were amended to reduce the exercise price and extend the termination date to October 4, 2024.
• The report also details indirect ownership of common stock by various Bios Funds.
• Aaron G.L. Fletcher, through his control over Bios Management and Bios Advisors, shares voting and investment control over the shares held by the Bios Equity Entities and may be deemed to beneficially own these shares.
• The reporting persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a regulatory filing detailing transactions. The continued investment by Bios Funds is a positive sign, but the complex ownership structure and disclaimers warrant caution.

Positives

• The purchase of units by Bios Clinical Opportunity Fund indicates continued investment in In8bio.
• The immediate exercisability of pre-funded warrants at a low price of $0.0001 could provide In8bio with immediate capital if exercised.
• Amendment of Series A warrants suggests a restructuring to potentially benefit both the investor and the company.

Risks

• The disclaimers of beneficial ownership by the reporting persons could indicate a complex ownership structure that may obscure true control.
• The dependence on Bios Funds for investment could pose a risk if their investment strategy changes.

Future Outlook

The document does not contain explicit forward-looking statements, but the transactions suggest continued involvement of Bios Funds in In8bio's financial activities.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders and major shareholders. The details of warrant purchases and amendments are relevant to understanding the company's capital structure and investor relations.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the US, ensuring transparency of insider transactions.
• The structure of the warrant purchase agreement, including pre-funded and Series C warrants, is a common financing mechanism used by biotech companies to raise capital.
• Comparable companies in the biotech sector, such as CRISPR Therapeutics or Beam Therapeutics, also regularly file Form 4s to report insider transactions.

Related Party Transactions

• The transactions involve related parties, including Aaron G.L. Fletcher and various Bios Funds, which are entities managed and controlled by him.
• The purchase of units and amendment of warrants are transactions between the company and these related parties.

Stakeholder Impact

• The transactions could impact shareholders by potentially diluting existing shares if the warrants are exercised.
• The capital raised could benefit the company's operations and development programs, positively impacting employees and potentially customers in the long term.

Key Dates